Back to top
more

Entera Bio (ENTX)

(Delayed Data from NSDQ)

$1.80 USD

1.80
19,627

-0.01 (-0.55%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $1.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Medical Stocks Lagging Argenx (ARGX) This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.

ENTX & OPK Stock May Gain Following Positive PK/PD Research Data

by Zacks Equity Research

Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.

Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year.

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy

by Zacks Equity Research

Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

by Zacks Equity Research

AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.

Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year.

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

by Zacks Equity Research

Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.

Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus

by Zacks Equity Research

Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

by Zacks Equity Research

AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

by Zacks Equity Research

Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.

Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data

by Zacks Equity Research

Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

by Zacks Equity Research

Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.

Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M

by Zacks Equity Research

Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.

Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why

by Zacks Equity Research

Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.

Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study

by Zacks Equity Research

The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.

GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals

by Zacks Equity Research

GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule

Sanofi (SNY) Signs Deal for AI-Powered Drug Development

by Zacks Equity Research

Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.

J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition

by Zacks Equity Research

Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.

Vanda (VNDA) Rises on Positive Data From Motion Sickness Study

by Zacks Equity Research

Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.

Are Medical Stocks Lagging Entera Bio (ENTX) This Year?

by Zacks Equity Research

Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.

Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

by Zacks Equity Research

Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.